166 related articles for article (PubMed ID: 8426494)
41. [Peptides used in lowering the level of LDL in plasma when treating familial hypercholesterolemia].
Sun L; Yue Y; Yu X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):336-9. PubMed ID: 12856614
[TBL] [Abstract][Full Text] [Related]
42. Pulsed flow cascade filtration. Long-term experience in low density lipoprotein and lipoprotein a removal.
Legallais C; Moriniére P; Fournier A; Jaffrin MY
ASAIO J; 1996; 42(5):M463-7. PubMed ID: 8944924
[TBL] [Abstract][Full Text] [Related]
43. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject.
Ketomaki A; Gylling H; Miettinen TA
J Lab Clin Med; 2004 Apr; 143(4):255-62. PubMed ID: 15085084
[TBL] [Abstract][Full Text] [Related]
44. [The plasma antioxidant status and trace elements in patients with familial hypercholesterolemia treated with LDL-apheresis].
Delattre J; Lepage S; Jaudon MC; Bruckert E; Assogba U; Bonnefont-Rousselot D
Ann Pharm Fr; 1998; 56(1):18-25. PubMed ID: 9770031
[TBL] [Abstract][Full Text] [Related]
45. Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial.
Tasaki H; Yamashita K; Saito Y; Bujo H; Daida H; Mabuchi H; Tominaga Y; Matsuzaki M; Fukunari K; Nakazawa R; Tsuji M; Kawade Y; Yamamoto S; Ueda Y; Takayama K
Ther Apher Dial; 2006 Feb; 10(1):32-41. PubMed ID: 16556134
[TBL] [Abstract][Full Text] [Related]
46. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
Gordon BR; Saal SD
J Clin Apher; 1996; 11(3):128-31. PubMed ID: 8915816
[TBL] [Abstract][Full Text] [Related]
47. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.
Sachais BS; Katz J; Ross J; Rader DJ
J Clin Apher; 2005 Dec; 20(4):252-5. PubMed ID: 15880364
[TBL] [Abstract][Full Text] [Related]
48. [H.E.L.P. apheresis and oxidative stress].
Pulawski E; Mellwig KP; Horstkotte D
Z Kardiol; 2003; 92(Suppl 3):III38-41. PubMed ID: 14663600
[TBL] [Abstract][Full Text] [Related]
49. Long term effect of LDL apheresis on coronary heart disease.
Donner MG; Richter WO; Schwandt P
Eur J Med Res; 1997 Jun; 2(6):270-4. PubMed ID: 9182655
[TBL] [Abstract][Full Text] [Related]
50. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.
Opole IO; Belmont JM; Kumar A; Moriarty PM
Am J Cardiol; 2007 Nov; 100(9):1416-8. PubMed ID: 17950800
[TBL] [Abstract][Full Text] [Related]
51. Is lipoprotein (a)-apheresis useful?
Bambauer R
Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
[TBL] [Abstract][Full Text] [Related]
52. Removal of cholesterol from blood by affinity binding to heparin-agarose: evaluation on treatment in homozygous familial hypercholesterolemia.
Lupien PJ; Moorjani S; Lou M; Brun D; Gagné C
Pediatr Res; 1980 Feb; 14(2):113-7. PubMed ID: 7360525
[TBL] [Abstract][Full Text] [Related]
53. Comment on "Homozygous familial hypercholesterolemia with severe involvement of the aortic valve: A sibling-controlled case study on the efficacy of lipoprotein apheresis".
Sbrana F; Dal Pino B; Bigazzi F; Sampietro T
J Clin Apher; 2021 Feb; 36(1):219-220. PubMed ID: 33002236
[No Abstract] [Full Text] [Related]
54. Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.
Vuorio A; Raal F; Klingel R; Kovanen PT
J Clin Lipidol; 2021; 15(2):379-380. PubMed ID: 34099192
[No Abstract] [Full Text] [Related]
55. Optimal management of familial hypercholesterolemia: treatment and management strategies.
Nemati MH; Astaneh B
Vasc Health Risk Manag; 2010 Dec; 6():1079-88. PubMed ID: 21191428
[TBL] [Abstract][Full Text] [Related]
56. [The effect of plasmapheresis and the plasmasorption and immunosorption of low-density lipoproteins on the humoral immunity function of patients with hereditary hypercholesterolemia].
Konovalov GA; Osipov SG; Kushekbaeva AE; Nasonov EL; Kukharchuk VV
Ter Arkh; 1990; 62(1):39-42. PubMed ID: 2333615
[TBL] [Abstract][Full Text] [Related]
57. International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?
Pang J; Lansberg PJ; Watts GF
J Atheroscler Thromb; 2016 May; 23(5):505-19. PubMed ID: 26903443
[TBL] [Abstract][Full Text] [Related]
58. Management of homozygous familial hypercholesterolaemia--unmet needs, updated recommendations, and clinical experience with the MTP inhibitor, lomitapide. Concluding comments.
Catapano AL
Atheroscler Suppl; 2014 Sep; 15(2):52. PubMed ID: 25257077
[No Abstract] [Full Text] [Related]
59. Homozygous familial hypercholesterolaemia: development of xanthogranuloma in a boy at puberty under long-term low-density lipoprotein apheresis and drug therapy.
Saito M; Tada Y; Harada-Shiba M; Yamamoto A; Kusakabe N; Yokogawa M; Kodama H; Asada H; Miyagawa S
Br J Dermatol; 2003 Dec; 149(6):1302-3. PubMed ID: 14674920
[No Abstract] [Full Text] [Related]
60. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Ito MK; McGowan MP; Moriarty PM;
J Clin Lipidol; 2011 Jun; 5(3 Suppl):S38-45. PubMed ID: 21600528
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
